AbbVie’s lost exclusivity for Humira is offset by immunology and neurology sales, diversified by its emerging oncology ...

Public markets are showing early signs of reopening, as Q4 2025 saw a 157% increase in IPO deal volume compared to Q4 2024.

Agenus has completed a $141m strategic collaboration with Zydus Lifesciences to accelerate the global development and ...

Clinical and commercial quality controls are eased as the FDA looks to expedite therapy approvals in areas of unmet need.

Madrigal’s strategy of pursuing combination therapies while the market remains in its infancy could intrinsically link its ...

As clinical trials generate ever larger and more complex datasets, platform-based approaches offer more efficient solutions.

Eli Lilly highlighted 2025 as the rollout year for obesity drugs, with Mounjaro at the forefront of its weight-loss portfolio ...

Novo Nordisk is positioning itself as a long‑term leader across multiple obesity segments rather than relying on a single ...

Amgen is hoping to gain a slice of the obesity market with MariTide, which it claims has a differentiated profile to other ...

AbbVie's deal with RemeGen is the first to be announced during the 2026 J.P Morgan Healthcare Conference, with more deals ...

Tremfya and Icotide are touted as key growth drivers in J&J’s strongly performing innovative medicines business.

AbbVie is now one of 16 big pharma companies to sign MFN deals with the Trump administration and commit to the expansion of ...